一品红(300723.SZ)：全资子公司创新药APH03621片获得临床试验注册申请受理

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. has received acceptance for its clinical trial application for the innovative drug APH03621 from the National Medical Products Administration, indicating progress in its development for treating endometriosis [1] Group 1: Company Developments - APH03621 is a new oral, non-peptide small molecule GnRH antagonist developed by the company, aimed at treating endometriosis [1] - The drug has not been approved for sale in domestic or international markets [1] - The specifications for APH03621 are 5mg and 40mg, classified as a new compound with pharmacological effects [1] Group 2: Regulatory Aspects - The drug falls under the category of innovative drugs that have not been marketed domestically or internationally, classified as Category 1 in chemical drug registration [1] - The acceptance of the clinical trial application is in accordance with the Drug Registration Management Measures and the requirements for chemical drug registration [1]